Osteoclast-targeted therapy for prostate cancer

Current Treatment Options in Oncology

Volumn 5, Issue 5, 2004, Pages 367-375

  Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUPRORELIN; MITOXANTRONE; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE PAIN; CANCER RISK; CANCER SURVIVAL; CELL ACTIVATION; CLINICAL TRIAL; DIETARY INTAKE; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; FRACTURE; HEMATOPOIESIS; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; HYPERPARATHYROIDISM; KIDNEY DYSFUNCTION; LIFESTYLE; MALE; METASTASIS POTENTIAL; MORBIDITY; OSTEOCLAST; OSTEOPOROSIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPINAL CORD COMPRESSION; STRUCTURE ANALYSIS;

EID: 8344277452     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0027-1     Document Type: Review

References (26)

1. Harada M, Iida M, Yamaguchi M, Shida K: Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol 1992, 324:173-182.
2. Clarke NW, McClure J, George NJ: Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993, 24 286-290.
3. Clarke NW, McClure J, George NJ: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991, 68:74-80.
4. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15:1526-1536.
5. Berruti A, Dogliotti L, Bitossi R, et al.: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000, 164 1248-1253.
6. Murray RM, Grill V, Crinis N, et al.: Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001, 86:4133-4138.
7. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
8. Higano CS: Management of bone loss in men with prostate cancer. J Urol 2003, 170:S59-S63; discussion S64.
9. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 1997, 80:1652-1660.
10. Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7 377-387.
11. Rosen LS, Gordon D, Tchekmedyian S, et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
12. Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
13. Small EJ, Smith MR, Seaman JJ, et al.: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003, 21 4277-4284.
14. Ernst D, Tannock I, Venner P, et al.: Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc Am Soc Clin Oncol 2002, Abstract 705:177a.
15. Dearnaley DP, Sydes MR, Mason MD, et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003, 95:1300-1311.
16. Mason MD, Collaboratos MP: Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873) [abstract]. Proc Am Soc Clin Oncol 2004, 4511.
17. Diamond TH, Winters J, Smith A, et al.: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444-1450.
18. Smith MR, Eastham J, Gleason D, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing ADT for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
19. Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238-2245.
20. Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 1999, 84:3431-3434.
21. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
22. Giovannucci E, Rimm EB, Wolk A, et al.: Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998, 58:442-447.
23. Chan JM, Giovannucci E, Andersson SO, et al.: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998, 9:559-566.
24. Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998, 9:567-582.
25. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003, 423:337-342.
26. Bekker PJ, Holloway DL, Rasmussen AS, et al.: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.